We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Hepion Pharmaceuticals Inc (HEPA) USD0.0001

Sell:$0.49 Buy:$0.50 Change: $0.0099 (1.98%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.49
Buy:$0.50
Change: $0.0099 (1.98%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:$0.49
Buy:$0.50
Change: $0.0099 (1.98%)
Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Hepion Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development of drug therapy for treatment of chronic liver diseases. The Company is developing a treatment for non-alcoholic steatohepatitis (NASH), hepatocellular carcinoma (HCC), and other chronic liver diseases. Its cyclophilin inhibitor, rencofilstat, is being developed to offer benefits to address multiple complex pathologies related to the progression of liver disease. It is developing rencofilstat as its lead molecule. Rencofilstat is a compound that binds and inhibits the function of a specific class of isomerase enzymes called cyclophilins that regulate protein folding, in addition to other activities. It has developed and maintains an artificial intelligence deep machine learning (AI/ML) platform designed to understand disease processes and identify patients that are rencofilstat responders. In addition, its AI/ML can be used to further NASH and HCC clinical development programs.

Contact details

Address:
399 Thornall St
EDISON
08837-2236
United States
Telephone:
+1 (732) 9024000
Website:
https://hepionpharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
HEPA
ISIN:
US4268973025
Market cap:
$3.48 million
Shares in issue:
6.96 million
Sector:
Pharmaceuticals
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • John Brancaccio
    Executive Chairman of the Board, Interim Chief Executive Officer, Interim Chief Financial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.